



Tussigon® (hydrocodone/homatropine) – Updated Indication, New Boxed Warning

- In January 2017, the FDA approved [Tussigon \(hydrocodone/homatropine\)](#) for the symptomatic relief of cough in adults and children 6 years of age and older.
 - Tussigon was previously approved for this indication without age specifications.
- In line with a recent [FDA Drug Safety Communication](#), Tussigon has a new boxed warning discussing risks from concomitant opioid use with benzodiazepines or other central nervous system depressants.
- Warnings and precautions of Tussigon include respiratory depression, head injury and increased intracranial pressure, acute abdominal conditions, caution in pediatric use, general use, and special risk patients.
- The recommended dose of Tussigon for children 6 to 11 years of age is one-half tablet every 4 to 6 hours as needed, not to exceed three tablets in 24 hours.
- The recommended dose of Tussigon for adults and adolescents 12 years of age and older is one tablet every 4 to 6 hours as needed, not exceed six tablets in 24 hours.
- Tussigon is a Schedule II controlled substance.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.